Raymond Prudo-Chlebosz - Jan 1, 2024 Form 3 Insider Report for Akari Therapeutics Plc (AKTX)

Role
Director
Signature
/s/ Rachelle Jacques, as Attorney-in-Fact for Raymond Prudo-Chlebosz, M.D.
Stock symbol
AKTX
Transactions as of
Jan 1, 2024
Transactions value $
$0
Form type
3
Date filed
1/2/2024, 06:58 PM
Next filing
Jun 4, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AKTX Ordinary Shares, par value $0.0001 per share 2.33B Jan 1, 2024 Direct
holding AKTX Ordinary Shares, par value $0.0001 per share 38.7M Jan 1, 2024 Praxis Trustees Limited
holding AKTX Ordinary Shares, par value $0.0001 per share 801M Jan 1, 2024 RPC Pharma Limited

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AKTX Stock Option (Right to Buy) Jan 1, 2024 Ordinary Shares, par value $0.0001 per share 10M $0.00 Direct F1
holding AKTX Warrants (Right to Buy) Jan 1, 2024 Ordinary Shares, par value $0.0001 per share 9.21M $0.03 RPC Pharma Limited
holding AKTX Warrants (Right to Buy) Jan 1, 2024 Ordinary Shares, par value $0.0001 per share 7.5M $0.02 Direct
holding AKTX Warrants (Right to Buy) Jan 1, 2024 Ordinary Shares, par value $0.0001 per share 20.2M $0.02 Direct
holding AKTX Warrants (Right to Buy) Jan 1, 2024 Ordinary Shares, par value $0.0001 per share 41.7M $0.01 Direct
holding AKTX Warrants (Right to Buy) Jan 1, 2024 Ordinary Shares, par value $0.0001 per share 118M $0.01 Direct
holding AKTX Warrants (Right to Buy) Jan 1, 2024 Ordinary Shares, par value $0.0001 per share 118M $0.01 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Non-qualified stock option granted under the Issuer's 2023 Equity Incentive Plan. One-hundred percent (100%) of the stock option vests and becomes exercisable on the date of the Issuer's 2024 Annual General Meeting.

Remarks:

See Exhibit 24.1 - Power of Attorney